Leticia Delgado-Herrera

Title: Leticia Delgado-Herrera: Innovator in Pharmaceutical Treatments

Introduction

Leticia Delgado-Herrera is a prominent inventor based in Surrey, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of infections. Her innovative work has led to the development of a unique dosage regimen for a tiacumicin compound.

Latest Patents

Leticia holds a patent for a dosage regimen for a tiacumicin compound. This patent outlines a method for using the tiacumicin compound, including its stereo-isomers and polymorphs, for the oral treatment of Clostridium difficile infections (CDI) and associated diseases (CDAD). The regimen involves an initial treatment of 200 mg administered twice daily, followed by monitoring the patient's response and adjusting the treatment as necessary to reduce recurrence of the infection.

Career Highlights

Leticia is currently employed at Astellas Pharma Europe Ltd., where she continues to advance her research and development efforts. Her work is characterized by a commitment to improving patient outcomes through innovative pharmaceutical solutions.

Collaborations

Leticia has collaborated with notable colleagues, including Andreas Johannis Karas and Christopher Mark Longshaw. These partnerships have contributed to her success in the field and have fostered a collaborative environment for innovation.

Conclusion

Leticia Delgado-Herrera is a trailblazer in the pharmaceutical industry, with a focus on developing effective treatments for serious infections. Her contributions through her patent and collaborative efforts highlight her dedication to advancing medical science.